Phase 3
N=85
An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency Syndrome
Overactive Bladder
Bottom Line
View on ClinicalTrials.gov: NCT00131573 ↗Enrolled (actual)
85
Serious AEs
0.0%
Results posted
Nov 2013
Primary outcome: Primary: Average Number of Voids Per Day — NA; NA Average Number of Voids
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- bion (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Boston Scientific Corporation
- Primary completion
- Mar 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Average Number of Voids Per Day |
NA; NA | — |
| PRIMARY Freedom From Major Complications |
0; 0 | — |
Summary
The goal of this study is to investigate the safety and effectiveness of a new implanted device designed to treat Urinary Urgency-Frequency Syndrome.
Eligibility Criteria
Key Inclusion criteria
- Age 18 years and above.
- Diagnosed with urinary urgency-frequency syndrome.
- Have no reported history of urethral obstruction/stricture, bladder calculi or bladder tumor.
- Have normal upper urinary tract function.
- Be capable of giving informed consent.
- Be capable and willing to follow all study related procedures.
Key Exclusion Criteria
- Have any active implantable device regardless of whether stimulation status is ON or OFF.
- Are pregnant as confirmed by a urine pregnancy test or plan to become pregnant during the following 12 month period.
- Less than one year post partum and/or are breast-feeding.
- Have any large passive implant that contains metal located within 30 cm of the chair pad while seated (e.g., hip replacement).
- Have conditions requiring magnetic resonance imaging (MRI) evaluation.
- Have conditions requiring diathermy procedures.
- Have an inability to operate the bion Remote Control and bion Recharging System either by self or caregiver.
- Have diabetes with peripheral nerve involvement or have severe uncontrolled diabetes.
- Have history of coagulopathy or bleeding disorder.
- Have pelvic pain in the absence of voiding dysfunction.
- Have anatomical restrictions such that the study device placement is not possible.
- Are currently participating or have participated within the past 30 days in any clinical investigation involving or impacting urinary or renal function.
- Cannot independently comprehend and complete the questionnaires.
Data sourced from ClinicalTrials.gov (NCT00131573). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.